Abstract Recruitment of immune cells such as monocytes/ macrophages and dendritic cells (DCs) across the bloodbrain barrier (BBB) has been documented in diseases involving neuroinflammation. Neuroinvasion by HIV leads to neurocognitive diseases and alters the permeability of the BBB. Likewise, many HIV patients use drugs of abuse such as morphine, which can further compromise the BBB. While the role of monocytes and macrophages in neuroAIDS is well established, research demonstrating the presence and role of DCs in the CNS during HIV infection has not been developed yet. In this respect, this study explored the presence of DCs in the brain parenchyma of rhesus macaques infected with a neurovirulent form of SIV (SIV mac239 R71/17E) and administered with morphine. Cells positive for DC markers including CD11c (integrin), macDC-SIGN (dendritic cellspecific ICAM-3 grabbing nonintegrin), CD83 (a maturation factor), and HLA-DR (MHC class II) were consistently found in the brain parenchyma of SIV-infected macaques as well as infected macaques on morphine. Control animals did not exhibit any DC presence in their brains. These results provide first evidence of DCs' relevance in NeuroAIDS vis-à-vis drugs of abuse and open new avenues of understanding and investigative HIV-CNS inflictions.
Introduction
Chronic HIV infection is frequently accompanied by different neuropathologies known collectively as HIV-associated neurocognitive disorders (HAND), which vary in severity and include HIV-associated dementia (HAD) and HIV encephalitis (HIVE) (Shapshak et al. 2011) . The neurological effects of HIVE and HAD include neuroinflammation, lesions, and cognitive decline. The prevalence of HAND is becoming a major concern given the aging population of individuals affected by HIV, who are already at risk for age-related neurocognitive impairment and neurodegenerative diseases (Shapshak et al. 2011) . Due to effective management of disease via highly active anti-retroviral therapy (HAART), the HIV-1-positive senior population in the USA rose over 6 % between (Shapshak et al. 2011 . Evidence of neuroinvasion by HIV can be obtained very early during infection, long before symptoms of neuroAIDS arise (Spudich et al. 2011) . A pattern of drug abuse often coincides with individuals affected by HIV. Not only is HIV frequently transmitted via drug use, drug abusers infected with HIV are also more likely to be affected by HAND than infected non-users (Bokhari et al. 2011) .
The blood-brain barrier (BBB) normally controls cel lular infiltration into the CNS, but can be breached during neuroinflammatory disease. As a result of severe inflammation and infectivity of immune cells during HIVE, monocytes harboring the virus can cross the BBB, before differentiating into perivascular macrophages that act as viral reservoirs (Buckner et al. 2011; Orenstein et al. 1997) . While the role of monocytes and macrophages in HIV infection during neuroAIDS is well characterized, a concise investigation of the presence and role of dendritic cells (DCs) in the CNS during HIV is lacking. DCs are effective antigenpresenting cells of myeloid origin whose interaction with naïve T cells mediates an immune response (Ilarregui et al. 2009 ). In previous studies, we have shown real-time trafficking of DCs in the inflamed spinal cord of animals afflicted with EAE (experimental autoimmune encephalomyelitis), a mouse model for MS (Jain et al. 2010; Sagar et al. 2012) . Further, the role of CCL2 in the trafficking of DCs across the BBB has been established (Sagar et al. 2012) . Encephalitis that ensues from HIV-associated neurocognitive disorders, like MS, has an inflammatory component that compromises BBB permeability. HIV infection can result in modification of the BBB through changes in tight junction proteins and chemokine regulation (Annunziata 2003) . In this respect, CCL2 or MCP-1 (monocyte chemoattractant protein-1) has been implicated in HIV encephalitis (Buckner et al. 2011; Conant et al. 1998; Dhillon et al. 2008; Eugenin et al. 2006; Johnson et al. 2004; Lee et al. 2011; Zink et al. 2001) and is known to attract monocytes, thus being a measure for clinical disease progression in infected macaques ). Morphine has also been shown to upregulate platelet-derived growth factor, which leads to a reduction of the tight junction protein ZO-1 expression (Wen et al. 2011) . There is a small body of accumulating evidence that morphine may protect the brain against neurotoxicity during HIV infection, thereby managing to maintain a persistent, low viral load (Cloak et al. 2011) . Also, long-term opiate dependence may in fact slow down viral progression (Donahoe et al. 2009 ) attributing the variability in disease progression found by different studies to other stress factors such as intense opiate administration/withdrawal regimen and the use of different viral strains. However, high plasma and cerebral spinal fluid (CSF) viral loads (Bokhari et al. 2011; Kumar et al. 2006 ) along with BBB breach typically characterize morphine-administered virus-infected macaques giving way to severe inflammation and encephalitis. Additionally, morphine-administered rhesus macaque models of SIV have shown decreased antioxidant activity that can lead to oxidative tissue injury with more rapid disease progression (Perez-Casanova et al. 2008 and increased levels of CCR5 receptors on peripheral blood mononuclear cells allowing a further increase in infectivity (Suzuki et al. 2002) . In some monkeys administered with morphine, Tat sequence diversity correlated with slowerprogressing viremia (characterized by stable viral load and acquisition of opportunistic infections by 52 weeks post viral inoculation; (Noel and Kumar 2006) ) and diminished virus evolution in general across both rapid progressors (characterized by high viral load leading to death from severe encephalitis between 5 and 20 weeks post-inoculation) and slow progressors .
The study presented herein is the first to demonstrate the penetration of DCs in the CNS in the brain parenchyma of rhesus macaques infected with SIV and administered with morphine. Future studies will provide a better understanding of the physiology behind the detrimental neuroinflammatory effects of neuroAIDS on the CNS can lead to the creation of more effective therapeutic drugs.
Materials and methods

Macaques
Nine 2-to 3-year-old Indian rhesus macaques (Macaca mulatta) were purchased from the Caribbean Research Primate Center and individually housed in steel-holding cages in two dedicated rooms within the AAALAC-approved animal facility at the University of Kansas Medical Center. The monkeys were exposed daily to 12 h light-dark cycles and given laboratory chow and water ad libitum along with daily snacks. All cages were equipped with environmental enrichments. The animals were tested for tuberculosis, herpes B virus, and simian retrovirus and found negative in all these tests. All animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Kansas Medical Center. The animals were randomly divided into three groups: control (n=3), SIV only (n=3), and SIV+morphine (n=3). Morphine was administered intramuscularly (IM) four times daily, at 6-h intervals, at a dose of 3 mg/kg with a 1-ml syringe (27.5G needle). The SIV+morphine group macaques were gradually acclimated to morphine by starting with 1 mg/kg for 1 week and escalating to a final dose of 3 mg/kg. The SIV group animals were injected with saline IM at the same time intervals. Morphine administration was maintained throughout the study to avoid withdrawal effects. For all animal studies, clinical grade morphine was purchased from the University of Kansas Medical Center Pharmacy.
Infection
SIVmacR71/17E (Raghavan et al. 1999 ) was originally prepared from pooled brain homogenates from macaques infected with R17 and R71E, both of which cause encephalitis. Virus stock was prepared in CD8+ T cell depleted, ConA-activated macaque peripheral blood mononuclear cells and assayed for infectivity in CEMx174 cells and by plaque assay in GHOST Hi5 cells. The animals were inoculated intravenously with approximately 10 4 plaqueforming units of virus 9 weeks following initiation of morphine administration.
Routine collection of samples
Blood and CSF samples were collected at weekly intervals for the first month and monthly thereafter based on the previously published studies (Bokhari et al. 2011) . The animals were anesthetized with ketamine and peripheral blood was collected in EDTA. Approximately 1 ml of CSF was collected from the cisterna magna. Levels of circulating CD4 + and CD8 + T cells as well as viral loads in plasma and CSF were monitored for over 8 months post-virus inoculation (PI).
Necropsy
All monkeys were monitored daily for evidence of disease (diarrhea, respiratory difficulties, progressive neurological signs, etc.) and alterations in attitude, appetite, or behaviors suggestive of illness (lack of movement, severely withdrawn behavior, lack of eating and/or drinking, etc.). Once these symptoms become unresponsive to treatment, the monkeys were euthanized. In preparation for necropsy, the animals were deeply anesthetized with ketamine (3 mg/kg) and medetomidine (0.15 mg/kg) given IM. Laparotomies were then performed, and the animals were exsanguinated from the descending aorta and perfused transcardially with normal saline. Samples of all the tissues including brain were harvested. Brains were dissected and portions of the parietal cortex, basal ganglia, frontal cortex, occipital cortex, and brainstem were collected. Adjacent portions of each tissue were frozen in liquid nitrogen-cooled isopentane and stored frozen at −80°C for later determination of viral RNA content. Other portions were placed into cassettes and fixed in 4 % paraformaldehyde or 10 % formalin. These cassettes were then processed for routine histopathological analysis.
Antibodies
Mouse-anti-human-CD11c-Alexa Fluor 647 (Biolegend, San Diego, CA), mouse-anti-human-CD31-FITC (BD Pharmingen, San Jose, CA) and mouse-anti-human-CD83-PE (Biolegend), mouse-anti-human-HLA-DR-FITC (Biolegend) and mouseanti-macaque-DC-SIGN-PE (Santa Cruz Biotechnology, Santa Cruz, CA) fluorophore-conjugated primary antibodies were used for fluorescent immunohistochemistry analyses. The following reagent was obtained through the AIDS Research and Reference Reagent Program: SIVmac p27 Monoclonal Antibody (55-2 F12) from Dr Niels Pedersen (Higgins et al. 1992 ). Goatanti-mouse-Alexa Fluor 350 (Invitrogen, Carlsbad, CA) was used for secondary detection of SIV p27.
Fluorescent immunohistochemistry
Frozen frontal cortex coronal sections on glass slides were baked overnight at 55°C to firmly affix and dehydrate the tissue. Paraffin-embedded monkey brain tissue sections were deparaffinized in xylene and rehydrated in a graded series of alcohol. Briefly, slides were immersed twice in 100 % xylene for 3 min, followed by a 3-min wash with a 1:1 solution of xylene and 100 % ethanol. Slides were then washed in 100, 95, 70, and 50 % ethanol followed by a cold water bath, each for 3 min. Thereafter, slides were boiled in 10 mM sodium citrate pH 6.0 for 20 min, followed by two 5-min washes with Tris buffered saline (TBS)+0.025 % Triton X-100, then permeabilized for 30 min in 0.1 % triton X-100 in TBS. Slides were blocked in 10 % mouse serum with 1 % BSA in TBS for 2 h at room temperature. After blocking, the slides were stained with fluorophore-conjugated primary antibodies at a concentration of 1:100 overnight at 4°C. Two-step staining protocols were carried out in the case of SIV p27 detection, in which slides were probed for p27 at a concentration of 1:100 overnight at 4°C, followed by detection with goat-anti-mouse-Alexa Fluor 350 at a concentration of 1:5,000 for 1 h at room temperature. Slides were then probed with remaining antibodies as described above. Slides were washed thrice in TBS+0.025 % Triton X-100. Where indicated, slides were counter-stained with 1 μg/ml DAPI. Following staining, slides were dried and a series of ×40 and ×100 Z-stack images were collected using the Olympus IX81 inverted microscope and analyzed using 3I Slidebook software.
Results
We examined the presence of DCs in the CNS of SIV-infected rhesus macaques, a common model organism for human HIV infection. Three study groups were established: non-infected control animals, macaques infected with SIV, and macaques infected with SIV and administered chronic morphine. Macaques were infected with a particularly neurovirulent SIV strain derived from SIVmac239 known as R71/17E, which closely mimics HIV pathogenesis by infecting CD4 + T cells (Bokhari et al. 2011; Raghavan et al. 1999) . Animals were monitored for behavioral changes, and blood and CSF samples were routinely taken and measured for viral RNA content as number of Gag copies per milliliter to monitor disease (Fig. 1a) . Viral RNA in blood and CSF were detectable within 1 week post-inoculation and remained higher in the SIV+morphine group up until week 20. Thereafter, viral burden was comparable between SIV and SIV+morphine groups until week 51. Since the frontal cortices of macaque brains were utilized in the subsequent immunohistochemical staining, viral titers from these regions were also measured (as Fig. 1 CD11c + cells in brain parenchyma of SIV-infected rhesus macaques with high viral burden. a Average viral load (Gag copies per milliliter) over a period of 1-51 weeks post-viral inoculation in plasma (top, left panel) and CSF (top, right panel) in SIV-infected monkeys treated with morphine compared to those without morphine. b Frontal cortex tissue-specific viral RNA titer (Gag copies/million GAPDH copies) of control and SIV-infected macaques with or without morphine. Average viral loads and calculated standard error bars are presented from three macaques per group. c After IHC-P staining, individual blood vessels in the frontal cortex were identified by CD31 staining (green). The control group shows a mostly contained CD11c + population (red) within the microvasculature, whereas the SIV-infected and SIV+morphine animals demonstrate CD11c + cell presence (white arrow) in the brain parenchyma. Representative images at ×40 magnification are shown number of Gag copies per million GAPDH copies) to estimate tissue viral load upon autopsy at week 51. Viral load in frontal cortex showed higher but non-significant (p=0.5) increase in the SIV+morphine group as compared with the SIV only group (Fig. 1b) .
To confirm the presence of DCs in the brain parenchyma of infected animals, we probed coronal frontal cortex sections with CD11c (red) to detect DCs and CD31 (green) to demarcate vasculature. While in the control group immune cells remained within the vasculature, SIV-infected macaques with and without morphine both showed penetration of CD11c + cells into the surrounding perivascular regions, as highlighted by the white arrow in the middle panel (Fig. 1c) . Additionally, we consistently observed enhanced vasodilation in the morphine-treated group, a likely artifact of the compromised BBB (Wen et al. 2011) . In order to quantify these differences, DAPI counterstaining was done to enumerate the total number of cells visualized, six random frames per study group were obtained and the frequency of CD11c + cells was determined in each experimental sample. Both SIV and SIV+morphine animals exhibited a higher frequency of CD11c + cells, 3.9 %±0.2 standard error of mean (SEM) and 6.2±1.8 %, respectively, compared to the control group 1.0±1.0 % (Table 1) . While a small percentage of CD11c + cells (1.0 %) was detected in the control group, they remained entirely within the microvasculature, as depicted in Fig. 1c . We also performed the statistical analysis of the data to determine the p value between the control uninfected group to the SIV-infected or SIV-infected plus morphine-administered group. The comparison of DC numbers in Control versus SIV group was found to be significant (p≤0.05), while control versus SIV+morphine was close to being significant (p=0.07). SIV+Morphine group in general showed a higher frequency of CD11c + cells but the difference between SIV+Morphine and SIV only groups did not reach to the significance (p=0.3).
As CD11c is a marker of cells of the myeloid lineage, including macrophages and monocytes, we next validated the presence of DCs distinctively by observing DC-specific cell surface markers. As shown in Fig. 2a , we observed macaque-specific DC-SIGN (macDC-SIGN, red) positive cells in the brain parenchyma of SIV-infected macaques and SIV+morphine macaques, but not in the control group. To further validate the presence of these cells at the site of SIV lesions, we stained for the mature SIV Gag protein, p27 (blue), as well as macDC-SIGN (red) and CD31 (green). Interestingly, compared to control animals, we found sites of distinct perivascular cuffing in SIV-infected animals that clearly showed the accumulation of DCs around the microvasculature (Fig. 2b, overlay) . Perivascular cuffing, frequently seen in MS and EAE is the result of the accumulation of lymphocytes around the vasculature and is indicative of ongoing inflammation. In the SIV+morphine group, the phenomenon was more pronounced with DC infiltration into the surrounding tissue (Fig. 2b, bottom panel) . To further attest to the presence of DCs, markers representing maturation (CD83) and antigen-presenting abilities (HLA-DR) were examined. While the control images showed a small degree of non-specific auto fluorescence, the SIV-infected groups showed distinct cells positive for both HLA-DR (green) and CD83 (red) as highlighted by the red circle in the middle panel (Fig. 2c) , creating an even more convincing body of evidence demonstrating DC presence in the brain parenchyma.
Discussion
Dendritic cells are well-known antigen-presenting cells that play a key role in the generation of a robust immune response. As classic immunological sentinels, they participate not only in antigen presentation, but chronic immune cell activation through dysregulation of pro-inflammatory chemokines and cytokines such as TLR7 and IFN-α (O'Brien et al. 2011; Sabado et al. 2010 ) and lymphocyte infection. Despite years of effective disease control with HAART, both patients infected with HIV and macaques infected with SIV exhibit high levels of viral DNA and low-level inflammation in the CNS demonstrating the critical need for a better understanding of the neuropathogenesis of HIV (Eden et al. 2007; Zink et al. 2010) . Heroin, which is converted to morphine in the brain, is often abused by HIV-infected persons and can further exacerbate disease. For example, chronic morphine exposure can upregulate CCR5 expression on neutrophils, monocytes, and macrophages and may lead to increased infiltration of immune cells into the CNS (Bokhari et al. 2011 ). In addition, morphine, a known vasodilator, has been linked to increased permeability of the microvascular endothelial cells of the BBB (Potula et al. 2004; Wen et al. 2011) .
While the role of monocytes and macrophages in HIV infection and neuroAIDS has been extensively explored, current knowledge of the presence and role of DCs during neuroAIDS is inadequate. For the first time here, we provide direct evidence that DCs are present in the CNS during SIV infection. Macaques in our study were slow progressors, with viral infection lasting over 8 months after which they were euthanized. We expect that a greater viral load should be an indicator of higher infiltration of immune cells into the brain. Our finding of a slightly higher proportion of DCs infiltrating into the brain of morphine-treated virus-infected macaques (Table 1) correlates with observed higher viral titer in these macaques (Figs. 1a-b) . We first demonstrated the presence of CD11c + cells in the brain parenchyma of SIVinfected animals (Fig. 1c) and quantification verified an increased frequency of these cells in the CNS of infected animals upon SIV infection (Table 1) . Importantly, although we did not see a significant increase (due to small sample size and the fact that these macaques were slow progressors that only achieve mild to moderate encephalitis) in the number of transmigrated cells upon morphine exposure in infected animals, we did see increased vasodilation that reflects an enhanced neuropathology.
Since other myeloid-origin immune cells such as monocytes and macrophages also express CD11c, we extended our investigation to include more specific DC markers. For this, we assessed macDC-SIGN expression and clearly observed positive cells, which were lacking in the control animals (Fig. 2a) . Mac-DC-SIGN is the macaque homolog of DC-SIGN in humans and has been characteristic of DC-specific studies in SIV infection (Changyong et al. 2010; de Witte et al. 2008; Xia et al. 2009; Yu Kimata et al. 2002) . In general, DC-SIGN is considered a specific marker primarily for the tissue specific DCs (Soilleux et al. 2002) , a subset of BDCA-2 + plasmacytoid DC precursors, and monocyte-derived DCs (MDDCs). It was shown to be further expressed on certain tissue macrophages such as in the alveoli and lung of developing fetus; however, its expression disappeared after development of the fetal alveoli (Soilleux et al. 2002 ). DC-SIGN expression level was also measured at 65-fold higher in DCs versus monocytes (Geijtenbeek et al. 2000) . Lastly, to confirm our findings, we analyzed the presence of DC markers associated with cellular maturity. CD83 + cells isolated from blood and shown to have the characteristic cellular morphology and functional activities of DCs (Pichyangkul et al. 2001; Zhou and Tedder 1995) . This population of CD83 + cells typically expresses the highest levels of MHC class II molecules, a hallmark of DCs, when compared with other leukocyte lineages. As detailed in Fig. 2c , we observed CD83 + staining in SIV-infected animals, as well as HLA-DR + , which indicates the presence of MHC class II markers and the ability to carry out antigen presentation.
Recent work by others and us has established the trafficking of DCs into the CNS during other neuroinflammatory diseases such as EAE (Jain et al. 2010; Zozulya et al. 2009 ) and MS (Hatterer et al. 2008) . DCs in the CNS could also be differentiated from the circulating myeloid precursors (Ifergan et al. 2008) . Once in the CNS, DCs were found to act as potent APCs, activating T helper lymphocytes and allowing immune invasion and relapse in the CNS (Bailey et al. 2007; Greter et al. 2005) . These studies are the first to decisively determine the presence of DCs in the CNS of subjects with SIV and open a new area of research in the field of HIV neuropathogenesis. DC interaction with other immune cells may perpetuate the neuroinflammatory symptoms of neuroAIDS by contributing to the cytokine dys regulation occurring in the CNS. Exposure to drugs of abuse further impacts the neuropathogenesis associated with AIDS; however, the manner remains underexplored. The induced vulnerability of the CNS to infection only exacerbates the increase in neuronal apoptosis observed in the presence of both morphine and gp120 IIIB due to greater p38 MAPK activation (Hu et al. 2005 ). An important factor in the interaction between morphine and immune cells is the presence of the mu-opioid receptor, which is primarily targeted by morphine and is known to be present on DCs (Li et al. 2009 ). Morphine exposure causes lipopolysaccharide-matured DCs to display an increased T cell stimulatory capacity as well as increased IL-12 production through the p38 MAPK pathway (Messmer et al. 2006) . Given the known effects that morphine has on DCs, it is likely that these phenomena play a role in HIV pathogenesis. Further investigations would greatly advance the understanding of neuroAIDS by unraveling the mechanism of DC transmigration across the BBB and its function once present in the CNS. A better understanding of the role DCs and drugs of abuse play in neuroAIDS will lead to more effective drug therapies.
